15.1 Fluorescein Angiography Principles, Exciter/Barrier Filters & Injection Protocol

Fluorescein Angiography Principles, Exciter/Barrier Filters & Injection Protocol

Core Clinical Mandate: Fundus fluorescein angiography (FA) is a dynamic diagnostic imaging modality that evaluates the microvascular architecture, perfusion status, and endothelial barrier integrity of the retina and choroid. Precision in filter matching, rapid bolus administration, and baseline photographic documentation is paramount for diagnostic accuracy and board-level competency.

---

Physics of Luminescence and Sodium Fluorescein

Fluorescein angiography relies on the physical phenomenon of luminescence, specifically photoluminescence. Luminescence is the emission of light by a substance resulting from an electronic transition from an excited energy state to a ground state, occurring without significant thermal radiation (distinguishing it from incandescence).

Luminescence, Fluorescence, and Stokes Law

Photoluminescence is subdivided into two distinct physical processes based on electron spin states and transition lifetimes:

1. Phosphorescence: Involves an intersystem crossing where an excited orbital electron transitions from a singlet excited state to a triplet state (spins parallel). Because returning to the ground singlet state requires a forbidden spin-flip transition, energy emission occurs slowly over milliseconds, seconds, or hours after the excitation source ceases.
2. Fluorescence: Involves direct transitions between electronic states of identical multiplicity (singlet-to-singlet, S₁ → S₀). An orbital electron absorbs a photon of excitation light, elevating it to an unstable higher vibrational energy level within the first excited singlet state. Within 10⁻¹² seconds, non-radiative internal conversion and vibrational relaxation dissipate a small fraction of the absorbed energy as heat. Within 10⁻⁹ to 10⁻⁸ seconds (nanoseconds), the electron drops back to the ground state, emitting a photon of lower energy.

Because the emitted photon contains less energy than the absorbed photon ($E = h\nu = hc/\lambda$), the emitted light necessarily exhibits a longer wavelength and lower frequency than the excitation light. This fundamental physical principle is known as Stokes Law, and the numerical difference in nanometers between the absorption maximum and the emission maximum is termed the Stokes Shift.

Molecular Structure and Spectral Profile of Sodium Fluorescein

Sodium fluorescein is a synthetic organic dye of the xanthene class with the chemical designation resorcinolphthalein sodium salt:

• Empirical Chemical Formula: C₂₀H₁₀Na₂O₅
• Molecular Weight: 376.28 g/mol
• Solubility: Highly water-soluble, hydrophilic, dibasic acid salt

In human aqueous and blood environments at physiological pH (7.35–7.45), sodium fluorescein exists in a fully ionized, highly resonant quinoid form that maximizes fluorescent yield. When dissolved in circulating blood plasma:

• Peak Absorption (Excitation) Wavelength: 465 nm to 490 nm (blue light spectrum, maximal absorption at approximately 490 nm).
• Peak Emission Wavelength: 520 nm to 530 nm (yellow-green light spectrum, maximal emission at approximately 525–530 nm).
• Stokes Shift: Approximately 35 nm to 40 nm.

---

Fundus Camera Optical Architecture and Filter Matching

To capture true retinal and choroidal fluorescence without interference from the intense illumination flash, the fundus camera employs a specialized optical filter assembly consisting of an exciter filter and a barrier filter matched to the spectral characteristics of sodium fluorescein.

Exciter and Barrier Filter Specifications

1. The Exciter Filter:

   • Optical Position: Positioned in the illumination path directly in front of the electronic xenon flash tube and tungsten viewing lamp.
   • Filter Characteristics: Multi-cavity interference bandpass filter.
   • Spectral Bandpass: Transmits light exclusively between 465 nm and 490 nm (blue light), while absorbing or reflecting all other wavelengths (ultraviolet, green, red, and infrared).
   • Function: Illuminates the fundus with the exact band of blue light required to excite circulating fluorescein molecules.

2. The Barrier Filter (Emission Filter):

   • Optical Position: Positioned in the observation and photographic optical path between the patient's eye and the digital camera sensor / film plane.
   • Filter Characteristics: Sharp-cut yellow-green filter (dichroic or high-grade absorption filter).
   • Spectral Transmission: Transmits emitted yellow-green fluorescence between 520 nm and 530 nm (up to ~600 nm), while exhibiting high optical density (blocking) across wavelengths shorter than 500 nm.
   • Function: Prevents the intense reflected blue excitation light (which reflects off the cornea, crystalline lens, sclera, and retina) from reaching the camera sensor, ensuring that only light emitted by fluorescein luminescence forms the photographic image.

Filter Crossover, Aging, and Pseudofluorescence

The physical separation between the excitation peak (~490 nm) and emission peak (~525 nm) is only 35–40 nm. If the transmission curve of the exciter filter has an extended high-wavelength "tail" or the barrier filter has a low-wavelength "leak," their transmission curves will intersect. This spectral overlap is called filter crossover.

• Pseudofluorescence (False Fluorescence): When filter crossover occurs, reflected blue light from highly reflective ocular structures (such as myelinated nerve fibers, sclera, hard exudates, or calcified drusen) passes through the barrier filter without exciting fluorescein molecules. This registered light mimics true fluorescence on the angiogram.
• Filter Degradation: Repeated exposure to the intense heat and ultraviolet radiation of high-energy xenon flash tubes causes organic gelatin and dichroic coatings to degrade, bleach, or delaminate over time. Annual or biannual inspection of camera filters is necessary to verify filter integrity and rule out crossover.

---

Photographic Sequence and Pre-Injection Baseline Controls

A standardized photographic protocol must be executed before injecting the dye. Pre-injection images provide crucial baseline documentation, calibrate optical clarity, and detect autofluorescent structures that could otherwise be misinterpreted as leakage or staining.

Standard Pre-Injection Acquisition Protocol:
[Color Fundus Photo] → [Red-Free Monochromatic Photo] → [Pre-Injection Control Frames (Filters IN)] → [Time Zero Injection]

1. Color Fundus Photography

Stereoscopic color photographs (30°, 35°, or 50° field of view) of the macula, optic disc, and peripheral quadrants must be captured prior to angiography. They establish baseline color documentation of subretinal fluid, hemorrhages, pigmentation, and lipid exudates, providing a direct anatomical comparator for subsequent angiographic phases.

2. Monochromatic Red-Free Photography (Green Filter: 540–570 nm)

Red-free fundus photography utilizes a green transmission filter (peak transmission ~540–570 nm). Because hemoglobin within erythrocytes strongly absorbs green light, blood vessels, microaneurysms, and intraretinal hemorrhages appear intensely black or dark against the lighter background fundus.

Clinical diagnostic utility of red-free photography:

• Highlights subtle retinal nerve fiber layer (RNFL) defects (slit defects, wedge defects) in glaucoma and neuro-ophthalmic disease.
• Delineates internal limiting membrane (ILM) wrinkles, cellophane maculopathy, and epiretinal membranes.
• Identifies subtle macular drusen, retinal microaneurysms, and diabetic dot-and-blot hemorrhages.
• Differentiates retinal pigment epithelial (RPE) melanin changes from subretinal or intraretinal blood.

3. Pre-Injection Control Frames (Autofluorescence / Pseudofluorescence)

Immediately before venipuncture, the ophthalmic medical technologist must engage both the exciter filter and the barrier filter, set the flash generator to standard angiographic exposure levels, and capture a baseline photograph of the posterior pole. Because no sodium fluorescein has entered the vascular system, this frame should be completely black in a normal eye.

If structures appear hyperfluorescent on this pre-injection control frame, the technologist must differentiate two distinct clinical phenomena:

• True Fundus Autofluorescence (FAF): Pathological or anatomical structures that naturally emit fluorescence when excited by blue light without exogenous dye. Clinical examples include optic nerve head drusen (calcified acanthosomes), astrocytic hamartomas, lipofuscin accumulation within diseased RPE cells (e.g., Best vitelliform macular dystrophy, Stargardt disease), and the aging crystalline lens.
• Pseudofluorescence: Non-fluorescent, highly reflective structures (scleral crescents, colobomas, myelinated nerve fibers) that appear bright because worn or poorly matched filters permit reflected blue light to leak through the barrier filter.

---

Intravascular Pharmacokinetics and Dye Clearance

Plasma Protein Binding and the Free Fluorescein Fraction

Following intravenous administration into the systemic circulation, sodium fluorescein rapidly binds to circulating plasma proteins:

• 80% to 85% Bound Fluorescein: Bound predominantly to serum albumin (and to a minor extent, alpha-2 globulins). When fluorescein binds to albumin, its fluorescence is quenched (suppressed by approximately 80–90%) due to non-radiative energy dissipation and spatial alteration of the resonating fluorophore ring.
• 15% to 20% Free (Unbound) Fluorescein: Remains unbound in the aqueous plasma fraction. This unbound portion is responsible for virtually all visible fluorescence observed on the angiogram.

Free fluorescein molecules are small (molecular weight 376 Da; hydrodynamic radius ~0.55 nm). Consequently, free fluorescein diffuses readily through the fenestrated endothelial sinusoids of the choriocapillaris, but cannot pass through the intact tight junctions (zonula occludens) of the healthy retinal capillary endothelium (the inner blood-retinal barrier) or the retinal pigment epithelium (the outer blood-retinal barrier).

Hepatic Biotransformation and Renal Excretion Kinetics

• Hepatic Metabolism: Sodium fluorescein is rapidly metabolized in the liver via glucuronide conjugation into fluorescein monoglucuronide. Fluorescein monoglucuronide is also fluorescent, but its excitation-emission efficiency is dramatically lower (only ~4.5% of the fluorescence of parent sodium fluorescein).
• Renal Elimination: Approximately 90% of the administered dose is excreted through the kidneys into the urine within 24 to 36 hours via glomerular filtration and active renal tubular secretion. The remainder is cleared via biliary/fecal excretion.

Patient Education Regarding Benign Chromatic Manifestations

The ophthalmic medical technologist must provide proactive, anticipatory counseling to every patient before injection to avoid unnecessary emergency department visits:

1. Skin and Scleral Discoloration: The skin and conjunctival sclera will exhibit a pronounced yellowish or jaundiced hue for 6 to 12 hours post-injection as free dye diffuses through dermal capillaries.
2. Chromaturia (Urine Discoloration): Urine will turn a bright, fluorescent, yellow-orange or dark amber color for 24 to 36 hours (and up to 48 hours in patients with reduced renal clearance).
3. Skin Photosensitivity: Advise patients to avoid direct sun exposure and tanning beds for 24 hours, as dermal fluorescein can absorb ultraviolet/blue radiation and induce mild solar phototoxicity.

---

Clinical Administration Protocols and Injection Technique

Formulations: 10% vs. 25% Sodium Fluorescein Solutions

Sodium fluorescein is commercially packaged in sterile, single-use glass ampules or prefilled syringes in two standard concentrations, both formulated to deliver a total adult diagnostic dose of 500 mg:

Clinical Note: While the 25% formulation provides a tighter bolus with crisper transit phase distinction, its hyperosmolality causes more intense local pain and a higher risk of sterile tissue necrosis if subcutaneous extravasation occurs.

Pediatric and Weight-Adjusted Dosing Considerations

For pediatric patients or frail adults with significant low body mass, dosing must be calculated based on weight rather than administering the full 500 mg adult dose:

• Standard Pediatric Dose: 35 mg/kg body weight (or 7.7 mg/kg of active dye, equivalent to 0.07 mL/kg of 10% solution), up to a maximum adult ceiling of 500 mg (5.0 mL of 10%).

Venipuncture Selection and Rapid Bolus Administration

1. Vein Selection: Antecubital fossa veins (the median cubital vein, cephalic vein, or basilic vein) are the primary anatomical sites of choice. Veins on the dorsal aspect of the hand or wrist should be avoided whenever possible: they possess smaller calibers, fragile valves, greater tortuosity, and higher rates of painful extravasation, and the longer venous transit path from the hand disperses the bolus, degrading transit phase timing.
2. Catheter / Needle Gauge: A 21-gauge or 23-gauge butterfly infusion set with short flexible tubing (or a 20–22G IV catheter) is standard. A 25-gauge needle creates excessive fluid resistance, preventing the rapid injection speed required for angiographic transit imaging.
3. The Bolus Technique:
   • Confirm brisk venous blood flashback to verify intraluminal placement.
   • Inject the entire dye volume rapidly over 2 to 4 seconds. Slow infusion must be strictly avoided because it smears the intravascular dye front over 10–15 seconds, destroying temporal separation between arterial and venous transit phases.
   • Follow immediately with a 5.0 mL normal saline flush through the butterfly tubing port to flush residual dye out of anatomical dead space and propel the bolus toward the right atrium.
4. Timer Initiation (Time Zero, T=0):
   • The camera digital timer / stop clock is triggered precisely at the start of the dye injection (or standardized to the midpoint/conclusion of the 3-second bolus per clinic protocol). This establishes $T=0$ for all subsequent elapsed transit frame calculations.

Extravasation Prevention and Acute Infiltration Management

Extravasation occurs when sodium fluorescein infiltrates into the perivascular subcutaneous tissue rather than entering the venous lumen. It causes intense, burning pain, swelling, and localized yellow-orange staining of the skin.

Acute Extravasation Management Protocol:
1. HALT INJECTION IMMEDIATELY
2. Aspirate residual dye through needle before removing
3. Apply ICE PACK / COLD COMPRESS (15-20 min q1h)
4. ELEVATE the extremity above heart level
5. Monitor for subcutaneous tissue sloughing or necrosis

• Step 1: Halt the injection immediately at the first patient report of pain, resistance to plunger depression, or localized perivascular tissue swelling.
• Step 2: Attempt to aspirate residual extravasated fluid back through the butterfly needle before withdrawing it.
• Step 3: Apply cold compresses or ice packs immediately for 15 to 20 minutes every hour for the first 6–12 hours. Cold application induces localized vasoconstriction, limits lymphatic spread, reduces inflammation, and relieves pain. (Do not apply hot compresses initially, as heat promotes vasodilation and worsens local tissue edema).
• Step 4: Elevate the affected limb above the level of the heart to promote venous and lymphatic drainage.
• Step 5: Reassure the patient that the local bright-yellow subcutaneous stain will gradually resorb over several days. In severe cases involving large volumes of hyperosmolar 25% fluorescein, monitor closely for rare chemical cellulitis, sterile abscess, or cutaneous necrosis.